MENU
+Compare
EMBC
Stock ticker: NASDAQ
AS OF
Dec 3, 04:59 PM (EDT)
Price
$11.96
Change
-$0.34 (-2.76%)
Capitalization
716.78M

EMBC stock forecast, quote, news & analysis

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes... Show more

EMBC
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. EMBC showed earnings on November 25, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for EMBC with price predictions
Nov 28, 2025

EMBC sees MACD Histogram just turned negative

EMBC saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 25, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 33 instances where the indicator turned negative. In of the 33 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 25, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on EMBC as a result. In of 64 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

EMBC moved below its 50-day moving average on November 25, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for EMBC crossed bearishly below the 50-day moving average on November 28, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMBC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for EMBC entered a downward trend on November 10, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EMBC advanced for three days, in of 200 cases, the price rose further within the following month. The odds of a continued upward trend are .

EMBC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (9.233). P/E Ratio (7.562) is within average values for comparable stocks, (163.343). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.548). EMBC's Dividend Yield (0.049) is considerably higher than the industry average of (0.016). P/S Ratio (0.668) is also within normal values, averaging (110.831).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. EMBC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EMBC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

A.I.Advisor
published Dividends

EMBC paid dividends on September 15, 2025

Embecta Corp EMBC Stock Dividends
А dividend of $0.15 per share was paid with a record date of September 15, 2025, and an ex-dividend date of August 29, 2025. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 11.91B. The market cap for tickers in the group ranges from 246 to 201.13B. ISRG holds the highest valuation in this group at 201.13B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -0%. For the same Industry, the average monthly price growth was 7%, and the average quarterly price growth was 3%. NNNN experienced the highest price growth at 25%, while OTCFF experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -65%. For the same stocks of the Industry, the average monthly volume growth was -77% and the average quarterly volume growth was -57%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 61
Price Growth Rating: 59
SMR Rating: 80
Profit Risk Rating: 92
Seasonality Score: 15 (-100 ... +100)
View a ticker or compare two or three
EMBC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
N/A
Address
300 Kimball Drive
Phone
+1 862 401-0000
Employees
2200
Web
https://www.embecta.com